SOLICITATION NOTICE
B -- Study of Obesity and Pancreatic Cancer
- Notice Date
- 7/31/2010
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100151-KM
- Archive Date
- 8/31/2010
- Point of Contact
- Karri L. Mares, Phone: 3014357774, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
maresk@mail.nih.gov, cr214i@nih.gov
(maresk@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division Cancer Epidemiology and Genetics (DCEG), Nutritional Epidemiology Branch (NEB) plans to procure on a sole source basis the laboratory analysis of C-peptide, adipocytokine, and inflammatory biomarkers related to obesity and pancreatic cancer from Lady Davis Institute for Medical Research, 3999 Chemin Cote Sainte Catherine, Montreal Quebec, Canada H3T 1E2. The supplies and services herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106 (b)(1). The North American Industry Classification System code is 621511 business size standard is $13.5 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance shall be for twelve (12) months from date of award. Obesity, diabetes mellitus, and higher glucose and insulin concentrations have been associated with increased pancreatic cancer risk in observational studies. The contractor will evaluate biomarkers related to obesity, insulin resistance, and diabetes and pancreatic cancer risk. This will examine baseline serum concentrations of c-peptide (an indirect measure of insulin secretion), adiponectin and HMW adiponectin (an adipocyte-derived peptide implicated in both insulin sensitivity and inflammation) and transforming growth factor (TGF-B) (a marker for type 2 diabetes and subclinical pancreatitis). The contractor shall provide laboratory analysis of TGF-B and HMW adiponectin to be measured on up to 792 ATBC stored serum samples; adiponectin and c- peptide on up to 91 ATBC stored serum samples; leptin on up to 46 ATBC stored serum samples; and laboratory analysis of TGF-B, adiponectin, and c-peptide to be measured on up to 154 PLCO stored serum samples. In total, laboratory analysis of TGF-B will be measured on up to 946 serum samples; HMW adiponectin will be measured on up to 792 serum samples; c-peptide and adiponectin will be measured on up to 245 serum samples; and leptin on up to 46 serum samples. NCI investigators are analyzing specimens from the PLCO Screening Trial and ATBC Study to investigate the relationship between circulating levels of c-peptide, adiponectin, HMW adiponectin, leptin, and transforming growth factor (TGF-B) and the risk of developing pancreatic cancer. The laboratory at the Lady Davis Institute for Medical Research is uniquely qualified to carry out the laboratory analysis. The laboratory has measured c-peptide, adiponectin, leptin, and TGF-B under previous studies for the NCI; it is critical that the leptin assays of additional PLCO and ATBC samples to be measured by the NCI in studies of pancreatic cancer also be completed in this laboratory to ensure scientific comparability of data. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 11:00 AM EST, on August 16, 2010. For further information, please contact Karri Mares, Contract Specialist via electronic mail at maresk@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: NCI-100151-KM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100151-KM/listing.html)
- Record
- SN02224874-W 20100802/100731233338-692f804a2473f011a2b81098f910dddb (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |